In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…
Search results for: nail psoriasis
Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis
In clinical trials, secukinumab proved safe and effective as a long-term treatment for both palmoplantar and nail psoriasis…
Tofacitinib Treatment May Improve Nail Psoriasis
NEW YORK (Reuters Health)—The oral Janus kinase (JAK) inhibitor tofacitinib appears to improve moderate to severe nail psoriasis, according to a new study. “Nails are hard to treat in psoriasis and we need better treatments,” says Dr. Luis Garza, a dermatologist at Johns Hopkins School of Medicine in Baltimore, who was not involved in the research….
One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis
NEW YORK (Reuters Health)—Apremilast is effective in patients with difficult to treat psoriasis of the scalp and nails, according to long-term results of two phase 3 trials. Investigators had previously reported 16-week data from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2 trials. The new report includes…
Many Medications: Understanding the Biologic Management of Psoriasis
ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.
Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles
NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…
Susceptibility Loci Shed Light on Fundamental Pathways of Psoriasis
Investigators have described 15 new psoriasis susceptibility loci. The loci highlight the importance of the skin in both acquired and innate host defense and identify the innate immune response as a key factor in psoriasis.
From Basic Science to Clinical Treatments: An Update on PsA
Dr. Christopher Ritchlin provided insights into the underlying mechanisms of the immune system that promote disease activity in patients with psoriatic arthritis (PsA), the latest research on how to optimize therapy for PsA and more.
Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
FDA Approves Risankizumab-rzaa for PsA
Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.
- 1
- 2
- 3
- …
- 7
- Next Page »